Novartis AG ADR (NVS)vsOrganiGram Holdings Inc (OGI)
NVS
Novartis AG ADR
$160.50
-0.19%
HEALTHCARE · Cap: $302.86B
OGI
OrganiGram Holdings Inc
$0.83
-0.65%
HEALTHCARE · Cap: $117.60M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 18454% more annual revenue ($57.36B vs $309.18M). OGI leads profitability with a 28.0% profit margin vs 17.5%. OGI trades at a lower P/E of 1.9x. OGI earns a higher WallStSmart Score of 58/100 (C).
NVS
Hold48
out of 100
Grade: D+
OGI
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.6%
Fair Value
$95.76
Current Price
$160.50
$64.74 premium
Intrinsic value data unavailable for OGI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 34.0%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 49.4% year-over-year
Conservative balance sheet, low leverage
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -6.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.0%.
Bull Case : OGI
The strongest argument for OGI centers on P/E Ratio, Price/Book, Revenue Growth. Profitability is solid with margins at 28.0% and operating margin at -2.2%. Revenue growth of 49.4% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : OGI
The primary concerns for OGI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a value stock while OGI is a growth play — different risk/reward profiles.
OGI carries more volatility with a beta of 1.98 — expect wider price swings.
OGI is growing revenue faster at 49.4% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Bottom Line
OGI scores higher overall (58/100 vs 48/100), backed by strong 28.0% margins and 49.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →OrganiGram Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Organigram Holdings Inc. produces and sells cannabis and cannabis-derived products in Canada. The company is headquartered in Moncton, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?